Comparative Pharmacology
Head-to-head clinical analysis: BLEPH 30 versus OPTOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLEPH 30 versus OPTOMYCIN.
BLEPH-30 vs OPTOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BLEPH-30 is a topical formulation containing 30% sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, interfering with folic acid synthesis and exerting bacteriostatic activity against susceptible organisms.
Optomycin is a semi-synthetic glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing transpeptidation and cross-linking.
One drop to the affected eye(s) every 12 hours. Not to exceed 2 drops per eye per day.
1.5 mg/kg IV every 8 hours; alternatively, 5-7 mg/kg IV daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5 hours in adults with normal renal function; clinically, dosing intervals may need adjustment in renal impairment.
3-5 hours (terminal half-life); prolonged to 10-20 hours in renal impairment.
Primarily renal excretion of unchanged drug, accounting for approximately 90% of elimination; minor biliary/fecal route (<10%).
Renal: 75-90% unchanged; biliary: 5-10%; fecal: <5%.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination